“First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience”. Mediterranean Journal of Hematology and Infectious Diseases 18, no. 1 (September 1, 2026): e2026066. Accessed September 2, 2026. https://www.mjhid.org/mjhid/article/view/6449.